இந்தியன் கட்டுப்பாட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pharmacovigilance is vital as more vaccines become available and new side-effects seen As India grapples with a vaccine shortage, the Drug Controller General of India has formally approved another vaccine candidate Sputnik V under emergency use authorisation. Since January, India’s vaccination strategy has hinged almost entirely on Covishield the AstraZeneca vaccine and to a very limited extent, Covaxin. Another significant move by the government is in allowing foreign-made vaccines approved by regulatory agencies in the U.S., the U.K., Europe, Japan or those that find mention in the World Health Organization’s list of approved emergency use vaccines which can avoid conducting a local clinical trial but opt for a parallel bridging trial post-approval. Last year, Pfizer had approached Indian regulators for permission but a sticking point was over this question of the conduct of local trials. It is important to note that bridging trials are critical. A vaccine that is app

World health organizationDrug controller generalAnother beginningMore vaccinesNew side effectsVaccine shortageDrug controller general of indiaVaccine candidateSputnik vEmergency use authorisationIndias vaccination strategyAstrazeneca vaccineForeign made vaccinesApproved by regulatory agenciesWorld health organizations list of approved emergency use vaccinesLocal clinical trial